Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: GSK/Angiochem; GSK/Daiichi Sankyo; Dainippon Sumitomo/Boston Biomedical

Executive Summary

In the latest of a series of rare disease deals, GlaxoSmithKline has forged a collaboration with Montreal-based Angiochem to develop drugs that cross the blood-brain barrier to treat patients with lysosomal storage diseases like Tay-Sachs disease and Fabry disease.

You may also be interested in...



Abbott Pays Top Dollar For Galapagos’ Autoimmune Drug

As its pharma division separates from its diversified medical products unit, Abbott obtains another drug that could succeed Humira in rheumatoid arthritis and related indications.

Dainippon Buys Boston Biomedical To Build On Cancer Strategy

Japanese pharma Dainippon will gain two clinical-stage novel drugs targeting cancer stem cells and a drug-discovery platform with the acquisition of Boston Biomedical for $200 million upfront and substantial milestones.

Sandoz Looks To Biosimilars As It Reprioritizes In The US

Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.

Topics

Related Companies

UsernamePublicRestriction

Register

PS054253

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel